STAAR Surgical Co. 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended July 3, 1998, and the six-month period ended on that date. STAAR Surgical Company is a Delaware corporation headquartered in Monrovia, California, specializing in ophthalmic products, including the Implantable Contact Lens and Glaucoma Wick. The company operates internationally with significant sales in Europe.
Key Financial Metrics (Six Months Ended July 3, 1998)
- Total Revenues: $28,083,711 (Sales: $27,967,640; Royalty Income: $116,071).
- Gross Profit: $19,972,070 (Gross Margin: 71.1%).
- Operating Income: $5,474,691.
- Net Income: $3,198,178 (Diluted EPS: $0.22).
- Cash Flow from Operations: $4,344,069.
- Cash and Cash Equivalents: $3,734,705 (down from $6,279,136 at Jan 2, 1998).
- Total Assets: $71,228,031.
- Total Liabilities: $23,236,250.
- Stockholders' Equity: $47,353,950.
- Current Ratio: 2.8:1.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26.9% compared to the six months ended July 4, 1997. This was driven by an $8.8 million increase in international sales, largely due to a new foreign distributor acquired in January 1998 and new product rollouts.
- Margin Compression: Gross margin decreased from 76.7% to 71.1%. Cost of sales rose to 28.9% of revenue, attributed to the higher cost of non-manufactured products from the new foreign subsidiary.
- Expense Increases: Marketing and selling expenses rose 48.3% in dollar terms (32.7% of revenue vs. 28.0% prior year) due to the new distributor. General and administrative expenses increased 7.7% but decreased as a percentage of revenue (12.0% vs. 14.1%) due to revenue absorption.
- Net Income Decline: Net income decreased 13.6% to $3.2 million, despite revenue growth, due to higher operating expenses and a minority interest charge of $346,990 related to the new subsidiary.
- Balance Sheet: Goodwill increased significantly to $4.9 million following the acquisition. Accounts payable rose to $4.7 million. Cash decreased by $2.5 million primarily due to debt repayments and inventory buildup.
Outlook, Risks, and Management Commentary
- Acquisition Impact: The company acquired a 60% interest in a foreign distributor for approximately $4.6 million. Management expects cost of sales percentages to decline as the subsidiary's product mix shifts toward company-manufactured goods.
- Year 2000 Compliance: A task force has been established to assess Y2K compliance. Management expects internal systems to be compliant without material financial impact, though contingency plans are being developed for suppliers.
- Liquidity: The company maintains a current ratio of 2.8:1 and net working capital of $24.2 million. Management expects future cash needs to be met by operations or additional financing if required.
- Risks: International operations expose the company to exchange rate fluctuations, foreign government regulations, and political instability. Competitive pressures continue to affect average selling prices for intraocular lenses (IOLs).
Investor Verification Checklist
- Verify the integration progress and cost structure improvements of the newly acquired foreign distributor.
- Monitor the trend of gross margins as the product mix shifts from non-manufactured to manufactured goods.
- Assess the impact of competitive pricing pressures on the core IOL product line.
- Review the status of Year 2000 compliance for critical suppliers and vendors.
- Confirm the sustainability of international sales growth in Europe and other key markets.